[go: up one dir, main page]

UY36608A - Derivados de indol - Google Patents

Derivados de indol

Info

Publication number
UY36608A
UY36608A UY0001036608A UY36608A UY36608A UY 36608 A UY36608 A UY 36608A UY 0001036608 A UY0001036608 A UY 0001036608A UY 36608 A UY36608 A UY 36608A UY 36608 A UY36608 A UY 36608A
Authority
UY
Uruguay
Prior art keywords
compounds
general formula
well
relates
present
Prior art date
Application number
UY0001036608A
Other languages
English (en)
Inventor
Dr Beke Gyula
Dr Éles János
Dr Boros András
Dr Farkas Sándor
Dr Keseru György Miklós
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of UY36608A publication Critical patent/UY36608A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula general (I),La presente invención se relaciona con nuevos derivados de diazepino-indol sustituido de la fórmula general (I), y con sales farmacéuticamente aceptable de los mismos, así como también con composiciones farmacéuticas que comprenden dichos compuestos, con nuevos intermedios de los mismos, así como también con el uso de dichos compuestos en tratamiento o prevención de trastornos asociados con actividad receptora de hormona que concentra melanina.
UY0001036608A 2015-04-15 2016-04-06 Derivados de indol UY36608A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1500169A HU230880B1 (hu) 2015-04-15 2015-04-15 Indol származékok

Publications (1)

Publication Number Publication Date
UY36608A true UY36608A (es) 2016-09-30

Family

ID=89991787

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036608A UY36608A (es) 2015-04-15 2016-04-06 Derivados de indol

Country Status (34)

Country Link
US (1) US10329296B2 (es)
EP (1) EP3286193B1 (es)
JP (1) JP6783793B2 (es)
KR (1) KR102591750B1 (es)
CN (1) CN107466294B (es)
AR (1) AR104261A1 (es)
AU (1) AU2016248969B2 (es)
CA (1) CA2982232C (es)
CL (1) CL2017002605A1 (es)
CO (1) CO2017011511A2 (es)
CU (1) CU24451B1 (es)
CY (1) CY1123185T1 (es)
DK (1) DK3286193T3 (es)
EA (1) EA034427B1 (es)
ES (1) ES2804519T3 (es)
GE (1) GEP20207067B (es)
HR (1) HRP20201289T1 (es)
HU (2) HU230880B1 (es)
IL (1) IL254711B (es)
LT (1) LT3286193T (es)
MX (1) MX2017013201A (es)
MY (1) MY189372A (es)
PE (1) PE20180196A1 (es)
PH (1) PH12017501736B1 (es)
PL (1) PL3286193T3 (es)
PT (1) PT3286193T (es)
RS (1) RS60605B1 (es)
SA (1) SA517390161B1 (es)
SG (1) SG11201707772RA (es)
SI (1) SI3286193T1 (es)
TW (1) TWI703145B (es)
UA (1) UA121046C2 (es)
UY (1) UY36608A (es)
WO (1) WO2016166684A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére
HUP2200221A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt 4-[(5-klór-piridin-2-il)metoxi]-1-[3-(propán-2-il)-1H,2H,3H,4H,5H-[1,4]diazepino [1,7-a]indol-9-il]-1,2-dihidropiridin-2-on kristályos formái és ezek sói, valamint elõállításuk és alkalmazásuk
HUP2300374A1 (hu) 2023-11-03 2025-05-28 Richter Gedeon Nyrt 18F és 11C radioaktívan jelzett MCHR1 PET ligandumok

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8500370A (nl) * 1984-02-22 1985-09-16 Sandoz Ag Diazepinoindolen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
AU4316301A (en) * 2000-03-14 2001-10-08 Upjohn Co Novel 2,3,4,5-tetrahydro-1H-(1,4)diazepino(1,7a)indole compounds
MXPA06001638A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonistas del receptor de la hormona concentradora de melanina.
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
US7851622B2 (en) 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
JP5514716B2 (ja) 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2240481A1 (en) * 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
WO2010141539A1 (en) * 2009-06-03 2010-12-09 Glaxosmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011130086A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2011127643A1 (en) * 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
WO2012088124A2 (en) * 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
US8933079B2 (en) 2012-03-07 2015-01-13 Boehringer Ingelheim International Gmbh Pyridone and pyridazinone derivatives as anti-obesity agents
WO2013149362A1 (en) 2012-04-06 2013-10-10 Glaxosmithkline Llc 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
US20140163012A1 (en) * 2012-12-11 2014-06-12 Albany Molecular Research, Inc. Pyrido-/azepino-benzofuran and pyrido-/azepino-benzothiophene mch-1 antagonists, methods of making, and use thereof

Also Published As

Publication number Publication date
CU24451B1 (es) 2019-11-04
TWI703145B (zh) 2020-09-01
JP6783793B2 (ja) 2020-11-11
JP2018511637A (ja) 2018-04-26
AR104261A1 (es) 2017-07-05
SG11201707772RA (en) 2017-10-30
PE20180196A1 (es) 2018-01-26
CY1123185T1 (el) 2021-10-29
CA2982232C (en) 2023-03-28
PH12017501736A1 (en) 2018-03-12
AU2016248969B2 (en) 2020-03-12
KR102591750B1 (ko) 2023-10-19
AU2016248969A1 (en) 2017-11-09
TW201708226A (zh) 2017-03-01
EP3286193A1 (en) 2018-02-28
UA121046C2 (uk) 2020-03-25
HUE16718017T2 (hu) 2021-03-29
PL3286193T3 (pl) 2020-11-16
GEAP201914624A (es) 2019-10-10
DK3286193T3 (da) 2020-08-24
SI3286193T1 (sl) 2020-10-30
MY189372A (en) 2022-02-08
SA517390161B1 (ar) 2021-07-12
EA201792170A1 (ru) 2018-03-30
WO2016166684A1 (en) 2016-10-20
US10329296B2 (en) 2019-06-25
RS60605B1 (sr) 2020-08-31
PT3286193T (pt) 2020-08-26
CL2017002605A1 (es) 2018-03-16
US20180093989A1 (en) 2018-04-05
GEP20207067B (en) 2020-02-10
ES2804519T3 (es) 2021-02-08
EA034427B1 (ru) 2020-02-06
NZ736551A (en) 2024-08-30
CA2982232A1 (en) 2016-10-20
KR20170137130A (ko) 2017-12-12
CU20170128A7 (es) 2018-01-10
CN107466294A (zh) 2017-12-12
HK1243705A1 (en) 2018-07-20
IL254711B (en) 2021-06-30
MX2017013201A (es) 2018-02-09
HRP20201289T1 (hr) 2020-11-13
BR112017021843A2 (pt) 2018-07-10
HUP1500169A2 (en) 2016-10-28
IL254711A0 (en) 2017-11-30
CN107466294B (zh) 2020-01-17
LT3286193T (lt) 2020-08-10
EP3286193B1 (en) 2020-05-27
CO2017011511A2 (es) 2017-11-21
HU230880B1 (hu) 2018-11-29
PH12017501736B1 (en) 2022-07-22

Similar Documents

Publication Publication Date Title
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
ES3047826T3 (en) Bipyrazole derivatives as jak inhibitors
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2016001283A1 (es) Derivado de urea o sal farmacológicamente aceptable del mismo
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CR20180496A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2018004664A (es) Antagonistas de ep4.
UY36195A (es) Amidas de benzoxazinona como reguladores del receptor mineralocorticoide
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CY1123185T1 (el) Παραγωγα ινδολιου

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20240607